Business Description
Outlook Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US69012T2069
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.98 | |||||
Equity-to-Asset | -1.78 | |||||
Debt-to-Equity | -0.39 | |||||
Debt-to-EBITDA | 25.57 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.8 | |||||
3-Year EPS without NRI Growth Rate | 29 | |||||
3-Year FCF Growth Rate | 26.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | 55.25 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 67.51 | |||||
9-Day RSI | 57.57 | |||||
14-Day RSI | 49.99 | |||||
6-1 Month Momentum % | -26.78 | |||||
12-1 Month Momentum % | -39.19 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.07 | |||||
Quick Ratio | 1.07 | |||||
Cash Ratio | 0.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27 | |||||
Shareholder Yield % | -54.17 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -229.89 | |||||
ROIC % | -155.68 | |||||
ROC (Joel Greenblatt) % | 103.82 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | 111.82 | |||||
EV-to-EBITDA | 103.43 | |||||
EV-to-Forward-Revenue | 15.63 | |||||
EV-to-FCF | -2.1 | |||||
Earnings Yield (Greenblatt) % | 0.9 | |||||
FCF Yield % | -49.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Outlook Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -9.933 | ||
Beta | -1.8 | ||
Volatility % | 183.48 | ||
14-Day RSI | 49.99 | ||
14-Day ATR (€) | 0.200777 | ||
20-Day SMA (€) | 4.753 | ||
12-1 Month Momentum % | -39.19 | ||
52-Week Range (€) | 4.16 - 11.5 | ||
Shares Outstanding (Mil) | 23.66 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Outlook Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Outlook Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Outlook Therapeutics Inc Frequently Asked Questions
What is Outlook Therapeutics Inc(STU:41O)'s stock price today?
When is next earnings date of Outlook Therapeutics Inc(STU:41O)?
Does Outlook Therapeutics Inc(STU:41O) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |